Vir Biotechnology’s Phase 2 Data Show 66% of CHD Patients Achieve Undetectable HDV RNA with Tobevibart and Elebsiran

Majority of Patients Achieve Key Viral Suppression Endpoint at 48 Weeks

Vir Biotechnology (NASDAQ: VIR) announced that 66% of participants with chronic hepatitis delta (CHD) achieved undetectable hepatitis delta virus (HDV) RNA after 48 weeks of treatment with a monthly combination of two investigational drugs: tobevibart and elebsiran. This data, coming from the company’s Phase 2 SOLSTICE trial, was presented at the AASLD The Liver Meeting and simultaneously published in the New England Journal of Medicine.

Favorable Safety and Additional Biomarker Improvements Reported

The combination therapy also normalized liver enzymes in more than half of patients and demonstrated reductions in hepatitis B surface antigen (HBsAg)—a marker essential for viral replication. Notably, no participants experienced grade 3 or higher treatment-related adverse events, and no one discontinued therapy due to safety concerns. The most common side effects were mild to moderate and temporary.

Potential Breakthrough for an Unmet Medical Need in CHD

Chronic hepatitis delta is recognized as the most severe form of chronic viral hepatitis, often leading to rapid progression to cirrhosis, liver failure, or liver-related death. Currently, there are no approved treatments in the United States, and available options are very limited elsewhere. Against this backdrop, the combination of tobevibart and elebsiran, which target the virus at different stages of its lifecycle, is seen as a potential new hope for patients facing a lack of options.

This significant unmet need has already attracted regulatory attention. The program has received Breakthrough Therapy and Fast Track designations from the FDA, along with PRIME and orphan drug status from the European Medicines Agency (EMA).

Next Steps: Phase 3 ECLIPSE Program Underway, Data Expected 2027

Vir’s ECLIPSE program, which is evaluating the same drug combination in larger and more rigorous Phase 3 clinical trials, is now fully underway. Topline results are expected in the first quarter of 2027. These trials include comparisons to both standard of care and deferred treatment groups and aim to provide the key data needed for global regulatory submissions.

What Does This Mean for Patients and Investors?

The results from the SOLSTICE Phase 2 trial are promising—not just for their efficacy, but for the apparent safety of monthly dosing in a population with high unmet medical needs. While these findings mark an important milestone, final answers will await results from ongoing Phase 3 trials. The attention from global regulators suggests there is genuine momentum and urgency to address chronic hepatitis delta, making this a key area to watch as further data emerge in the coming years.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI